Jason Zhu

Jason Zhu

Auto-generated profile, based on publicly available information

Jason Zhu

Levine Cancer Institute, Atrium Health, Charlotte, NC

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JZJason Zhu
Jason Zhu
AAAndrew J Armstrong
Andrew J Armstrong
TFTerence W. Friedlander
Terence W. Friedlander
WKWon Kim
Won Kim
SPSumanta K Pal
Sumanta K Pal
TZTian Zhang
Tian Zhang
Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantification of PD-L1 was developed as a promising biomarker in early clinical trials, but many shortcomings of the four different assays (different antibodies, disparate cellular populations, and different thresholds of positivity) have limited its clinical utility. Further limitations include the use of archival specimens to measure this dynamic biomarker. Indeed, until PD-L1 testing is standardized and can consistently predict treatment outcome, the currently available PD-L1 assays are not clinically useful in urothelial and renal cell carcinoma. Other more promising biomarkers include tumor mutational burden, profiles of tumor infiltrating lymphocytes, molecular subtypes, and PD-L2. Potentially, a composite biomarker may be best but will need prospective testing to validate such a biomarker.

1 October 2011 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
ACAmy Y. Chen
Amy Y. Chen
SFStacey Fedewa
Stacey Fedewa
JZJason Zhu
Jason Zhu
Research from JAMA Otolaryngology–Head & Neck Surgery — Temporal Trends in the Treatment of Early- and Advanced-Stage Laryngeal Cancer in the United States, 1985-2007

1 June 2012 in Hearing Research
Verified
Journal Article
Closed access
XLXi Lin
Xi Lin
WTWenxue Tang
Wenxue Tang
SAShoeb Ahmad
Shoeb Ahmad
JLJingqiao Lu
Jingqiao Lu
CCCandice C. Colby
Candice C. Colby
QYQing Yu
Qing Yu

3 July 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
MTMatthew Tucker
Matthew Tucker
JZJason Zhu
Jason Zhu
DMDaniele Marin
Daniele Marin
RGRajan T. Gupta
Rajan T. Gupta
SGSantosh Gupta
Santosh Gupta
AAAndrew J Armstrong
Andrew J Armstrong
Background: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies.Methods: We performed a single institution retrospective review of men with metastatic castrate‐resistant prostate cancer (mCRPC) who were treated with pembrolizumab. The primary objective was to describe the clinical efficacy of pembrolizumab associated with patient and genomic characteristics.Results: We identified 48 men who received ≥1 cycle of pembrolizumab for mCRPC. Of these, 94% (45/48) had ≥3 prior lines of therapy for mCRPC. Somatic tumor sequencing was available in 18/48 men (38%). We found that 17% (8/48) had a ≥50% confirmed PSA decline with pembrolizumab, and 8% (4/48) had a ≥90% PSA decline with durations of response ranging from 3.1 to 16.3 months. Two of these four men had mutations in LRP1b, one of whom also had MSH2 loss and was MSI‐H and TMB‐high. Despite prior progression on enzalutamide, 48% (23/48) of men were treated with concurrent enzalutamide. The median PSA progression‐free‐survival was 1.8 months (range 0.4‐13.7 months), with 31% of patients remaining on pembrolizumab therapy and 54% of men remain alive with a median follow‐up of 7.1 months.Conclusions: In a heavily pretreated population of men with mCRPC, pembrolizumab was associated with a ≥50% PSA decline in 17% (8/48) of men, including a dramatic ≥90% PSA response in 8% (4/48), two of whom harbored pathogenic LRP1b mutations suggesting that LRP1b mutations may enrich for PD‐1 inhibitor responsiveness in prostate cancer.

6 July 2013 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
ACAmy Y. Chen
Amy Y. Chen
JZJason Zhu
Jason Zhu
SFStacey Fedewa
Stacey Fedewa

11 December 2014 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
TZTian Zhang
Tian Zhang
JZJason Zhu
Jason Zhu
DGDaniel J George
Daniel J George
AAAndrew J Armstrong
Andrew J Armstrong
Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The optimal sequencing of therapies in the context of efficacy and known cross-resistance remains uncertain. We review the development of enzalutamide (MDV3100, Xtandi), a novel second-generation androgen receptor (AR), and AA (Zytiga), a selective, irreversible inhibitor of cytochrome P17. In addition to discussing the clinical evidence, we also address evolving evidence of mechanisms of resistance and clinical cross-resistance during sequential therapy with these agents. AA and enzalutamide have both demonstrated tolerability and clinical benefit for multiple outcomes in patients with CRPC, in both post-chemotherapy and pre-chemotherapy settings. Both agents target the androgen-signaling pathway and have similar efficacy; however, they differ in prednisone use and their toxicity profiles, impacting the decision of upfront therapy. Mechanisms of resistance emerging after treatment include both alterations in AR signaling as well as mechanisms that bypass the AR. Retrospective analyses have demonstrated evidence that sequential treatment with these agents results in limited clinical benefit, supporting mechanisms of cross-resistance. Trials are ongoing to determine optimal timing, sequence and combination of these agents.